ABLi Therapeutics Revenue
Biotechnology Research • 
United States • 1-10 Employees
$
ABLi Therapeutics revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Key Contact at ABLi Therapeutics
Chris Meyer
COO and Co-Founder
Company overview
| Headquarters | United States |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
| Socials |
About ABLi Therapeutics
ABLi Therapeutics is a developing small molecule inhibitors to treat diseases resulting from Abelson Tyrosine Kinase dysfunction (Abl kinases or c-Abl). The Company is engineering its Abl kinase inhibitors to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other neurological diseases associated with Abl kinase dysfunction inside and outside of the brain.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
C-Suite
Employees by Department
ABLi Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
ABLi Therapeutics has never raised funding before.
India
Italy
Frequently asked questions
ABLi Therapeutics is located in US.
ABLi Therapeutics generates an estimated annual revenue of $256,665. This revenue figure reflects the company's market position and business performance in its industry.
ABLi Therapeutics has an estimated valuation of $821,328. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
ABLi Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
